In particular, high levels of EPHA2 correlate with adverse prognosis in triple-negative (TNBC), hormone receptor-positive, as well as HER2-positive BC, with EPHA2 participating in the resistance mechanisms against both antihormonal (antiestrogens) and targeted (trastuzumab) therapy [20]. The gene discussed is NR4A1; the disease is breast cancer.